Notably, with exception of BRAF, a well-known PTC driver gene, this study was the first to identify several genes with high frequency mutations in PTC, such as NCOR2, ANK3, BPTF, and PCSK5. A previous study reported that NCOR2, a nuclear receptor corepressor, serves as a potential drug target in the treatment of breast cancer by interacting with ER, and deficiency of NCOR2 may cause breast cancer (43). This evidence concerns the gene ESR1 and breast cancer.